

On-line Table 1: Wilcoxon rank sum test for proportion of enhancing meningeal foci persisting at 1 year versus demographic and clinical factors^a

	On Treatment	Not on Treatment	Progressive MS	Nonprogressive MS	EDSS	EDSS
	(n = 25) 1.00 (0.44–1.00)	(n = 6) 0.97 (0.50–1.00)	(n = 10) 1.00 (0.50–1.00)	(n = 21) 1.00 (0.44–1.00)	Progressor at 1 yr ^b	Nonprogressor at 1 yr ^b
Proportion of overall foci persisting at 1 yr	(n = 22) 1.00 (0.25–1.00)	(n = 6) 0.92 (0.00–1.00)	(n = 9) 1.00 (0.00–1.00)	(n = 19) 1.00 (0.25–1.00)	(n = 7) 1.00 (0.64–1.00)	(n = 24) 1.00 (0.44–1.00)
Proportion of subarachnoid spread/fill foci persisting at 1 yr	(n = 9) 1.00 (0.00–1.00)	(n = 1) 1.00 (1.00–1.00)	(n = 0)	(n = 10) 1.00 (0.00–1.00)	(n = 1) 0.00 (0.00–0.00)	(n = 9) 1.00 (0.50–1.00)
Proportion of subarachnoid nodular foci persisting at 1 yr	(n = 19) 1.00 (0.83–1.00)	(n = 6) 1.00 (0.75–1.00)	(n = 8) 1.00 (0.75–1.00)	(n = 17) 1.00 (0.83–1.00)	(n = 6) 1.00 (1.00–1.00)	(n = 19) 1.00 (0.75–1.0)
Proportion of dural foci persisting at 1 yr	(n = 14) 1.00 (1.00–1.00)	(n = 4) 1.00 (1.00–1.00)	(n = 7) 1.00 (1.00–1.00)	(n = 11) 1.00 (1.00–1.00)	(n = 4) 1.00 (1.00–1.00)	(n = 14) 1.00 (1.00–1.00)

Note:—Progressive MS indicates primary-progressive and secondary-progressive MS; Nonprogressive MS, relapsing-remitting MS.

^a Median values are listed with the range of observed values in parentheses.

^b Criteria for EDSS progressor status as listed in the “Materials and Methods” section.

On-line Table 2: Spearman ρ test for number of enhancing meningeal foci persisting at 1 year versus demographic and clinical factors

	Age (yr) ^a	Disease Duration (yr) ^a	EDSS at Baseline	Change of EDSS at 1 yr	MFS at Baseline	Change of MFS at 1 yr	SDMT at Baseline	Change of SDMT at 1 yr
No. of overall foci persisting at 1 yr (31 obs)	0.13	0.03	-0.10	0.35	0.05	-0.21	-0.16	0.28
No. of subarachnoid spread/fill foci persisting at 1 yr (31 obs)	0.20	0.21	0.12	0.30	-0.25	-0.15	-0.08	0.31
No. of subarachnoid nodular foci persisting at 1 yr (31 obs)	-0.10	-0.08	-0.17	-0.39 ^b	-0.15	0.00	0.12	0.23
No. of vessel wall foci persisting at 1 yr (31 obs)	0.06	0.09	-0.10	0.10	0.16	-0.27	-0.13	0.23
No. of dural foci persisting at 1 yr (31 obs)	-0.02	-0.24	-0.01	-0.01	0.05	-0.22	-0.15	0.13

Note:—obs indicates subjects; MFS, Modified Fatigue Impact Scale; SDMT, Symbol Digit Modalities Test.

^a At enrollment.

^b $P < .05$.

On-line Table 3: Spearman ρ test for proportion of enhancing meningeal foci persisting at 1 year versus demographic and clinical factors

	Age (yr) ^a	Disease Duration (yr) ^a	EDSS at Baseline	Change of EDSS at 1 yr	MFIS at Baseline	Change of MFIS at 1 yr	SDMT at Baseline	Change of SDMT at 1 yr
Proportion of overall foci persisting at 1 yr (31 obs)	0.04	-0.12	-0.20	-0.09	-0.13	0.08	0.45 ^b	-0.31
Proportion of subarachnoid spread/fill foci persisting at 1 yr (28 obs)	0.04	-0.08	-0.19	-0.09	-0.17	0.17	0.48 ^b	-0.26
Proportion of subarachnoid nodular foci persisting at 1 yr (10 obs)	0.02	0.27	-0.41	-0.76 ^b	-0.25	0.09	0.29	-0.15
Proportion of vessel wall foci persisting at 1 yr (25 obs)	0.10	-0.01	-0.23	0.16	-0.22	0.14	0.20	-0.11
Proportion of dural foci persisting at 1 yr (14 obs)	NA	NA	NA	NA	NA	NA	NA	NA

Note:—NA indicates not applicable because all participants had 100% persistence of this subtype and correlations with other variables could not be calculated; obs, subjects; MFIS, Modified Fatigue Impact Scale; SDMT, Symbol Digit Modalities Test.

^a At enrollment.

^b $P < .05$.